ANIP · Ani Pharmaceuticals Inc · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-10-15 | Lalwani Nikhil |
Director, PRESIDENT & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. The shares were sold in multiple trades at prices ranging from $71.08 to $72.56. The price reported above reflects the weighted average sales price. |
Common Stock
|
5,400 |
| 2026-10-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-09-29 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. The shares were sold in multiple trades at prices ranging from $72.57 to $73.86. The price reported above reflects the weighted average sales price. |
Common Stock
|
2,850 |
| 2026-09-15 | Lalwani Nikhil |
Director, PRESIDENT & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. |
Common Stock
|
5,400 |
| 2026-09-14 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-09-11 | Thoma Jeanne |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2026. |
Common Stock
|
1,000 |
| 2026-08-31 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. The shares were sold in multiple trades at prices ranging from $71.89 to $73.36. The price reported above reflects the weighted average sales price. |
Common Stock
|
2,850 |
| 2026-08-25 | Lalwani Nikhil |
Director, PRESIDENT & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2026. The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price. |
Common Stock
|
5,400 |
| 2026-08-19 | Gosebruch Henry O |
EVP, Chief Strategy Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026. |
Common Stock
|
6,662 |
| 2026-08-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-08-10 | Gutwerg Ori |
SVP, GENERICS |
Sell↓
|
Common Stock
|
3,162 |
| 2026-07-29 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. The shares were sold in multiple trades at prices ranging from $80.61 to $81.88. The price reported above reflects the weighted average sales price. |
Common Stock
|
2,850 |
| 2026-07-18 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,820 shares of restricted stock, the grant of which was previously reported on July 20, 2022. |
Common Stock
|
2,466 |
| 2026-07-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-07-02 | CAREY STEPHEN P. |
SVP & CFO |
Convert↑
Filing footnotes — Common Stock (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. |
Common Stock
|
3,313 |
| 2026-07-02 | CAREY STEPHEN P. |
SVP & CFO |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. |
Stock Option (right to buy)
|
3,313 |
| 2026-07-02 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. |
Common Stock
|
3,313 |
| 2026-06-29 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price. |
Common Stock
|
2,850 |
| 2026-06-12 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-06-08 | HAUGHEY THOMAS |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2026. |
Common Stock
|
2,000 |
| 2026-06-05 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. |
Common Stock
|
3,312 |
| 2026-06-05 | CAREY STEPHEN P. |
SVP & CFO |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. |
Stock Option (right to buy)
|
3,312 |
| 2026-06-05 | CAREY STEPHEN P. |
SVP & CFO |
Convert↑
Filing footnotes — Common Stock (Direct)
The stock option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. |
Common Stock
|
3,312 |
| 2026-05-21 | Pera Antonio R |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in full on May 21, 2027. |
Common Stock
|
4,357 |
| 2026-05-21 | TANNENBAUM RENEE P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in full on May 21, 2027. |
Common Stock
|
4,357 |
| 2026-05-21 | Leonard Matthew J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in full on May 21, 2027. |
Common Stock
|
4,357 |
| 2026-05-21 | HAUGHEY THOMAS |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in full on May 21, 2027. |
Common Stock
|
4,357 |
| 2026-05-21 | Thoma Jeanne |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock award that will vest in full on May 21, 2027. |
Common Stock
|
4,357 |
| 2026-05-13 | Walsh Patrick D |
Director |
Sell↓
|
Common Stock
|
10,000 |
| 2026-05-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-05-12 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS |
Sell↓
|
Common Stock
|
459 |
| 2026-05-12 | Gutwerg Ori |
SVP, GENERICS |
Sell↓
|
Common Stock
|
2,772 |
| 2026-05-11 | Walsh Patrick D |
Director |
Sell↓
|
Common Stock
|
3,973 |
| 2026-05-11 | Lalwani Nikhil |
Director, PRESIDENT & CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold in multiple trades at prices ranging from $76.21 to $80.38. The price reported above reflects the weighted average sales price. |
Common Stock
|
55,000 |
| 2026-04-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-03-13 | Mutz Christopher |
HEAD OF RARE DISEASE |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price. |
Common Stock
|
3,162 |
| 2026-03-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. |
Common Stock
|
500 |
| 2026-03-11 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS |
Sell↓
|
Common Stock
|
4,772 |
| 2026-03-09 | Mutz Christopher |
HEAD OF RARE DISEASE |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price. |
Common Stock
|
3,602 |
| 2026-03-09 | Davis Krista |
SVP, CHIEF HR OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. The shares were sold in multiple trades at prices ranging from $72.94 to $74.76. The price reported above reflects the weighted average sales price. |
Common Stock
|
5,087 |
| 2026-03-07 | Mutz Christopher |
HEAD OF RARE DISEASE |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported. |
Common Stock
|
3,314 |
| 2026-03-07 | Lalwani Nikhil |
Director, PRESIDENT & CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 33,352 shares of restricted stock, the grant of which was previously reported. |
Common Stock
|
17,060 |
| 2026-03-07 | CAREY STEPHEN P. |
SVP & CFO |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,292 shares of restricted stock, the grant of which was previously reported. |
Common Stock
|
5,150 |
| 2026-03-07 | Gutwerg Ori |
SVP, GENERICS |
Tax↓
Filing footnotes — Common Stock (Direct)
Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported. |
Common Stock
|
3,314 |
| 2026-03-06 | Davis Krista |
SVP, CHIEF HR OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2025. |
Common Stock
|
1,485 |
| 2026-03-06 | Mutz Christopher |
HEAD OF RARE DISEASE |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price. |
Common Stock
|
2,121 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO |
Convert↑
|
Common Stock
|
3,312 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold in multiple trades at prices ranging from $75.41 to $75.56. The price reported above reflects the weighted average sales price. |
Common Stock
|
3,312 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO |
Sell↓
|
Common Stock
|
4,000 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. |
Stock Option (right to buy)
|
3,312 |